



CERTIFICATE OF MAILING
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING
DEPOSITED WITH THE UNITED STATES POSTAL SERVICE WITH
SUFFICIENT POSTAGE AS FIRST-CLASS MAIL IN AN ENVELOPE
ADDRESSED TO: ASSISTANT COMMISSIONER FOR PATENTS,
WASHINGTON, D.C. 20231, ON MAY 7, 1999

Agent/Attorney for Applicant

May 99
DATE

Attorney Docket No. P31158

GAU 1614/02
H/M
5-14-99

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Vere Hodge et al. 7 May 1999
Serial No.: 08/945,249 Group Art Unit No.: 1614
Filed: 2 February 1998 Examiner: R. Travers
For: Use of (R)-Penciclovir Triphosphate For the Manufacture
of A Medicament For the Treatment of Viral Diseases

TRANSMITTAL LETTER

Transmitted herewith is an Amendment in the above-identified application.

EXTENSION OF TIME PETITION

Applicants hereby petition for an extension of time for response from the date of the Examiner's action as needed, the fee being as follows:

(<input type="checkbox"/>	one month extension.....	\$ 110
(<input checked="" type="checkbox"/>	two months extension.....	\$ 380
(<input type="checkbox"/>	three months extension.....	\$ 870
(<input type="checkbox"/>	four months extension (not beyond statutory time period).....	\$1360
(<input type="checkbox"/>	five months extension	\$1850

Charge \$380.00 to Deposit Account No. 19-2570. Two copies of this form are enclosed.

Please charge any additional fees under 37 CFR 1.16 or 1.17 which may be required by this paper, or credit any overpayment, to Deposit Account No. 19-2570. Also, should the Patent and Trademark Office determine that the fee calculated in the above extension petition is not deemed sufficient to have this response considered as being timely filed, this constitutes a petition for extension of time for the minimum period to effect timely filing, and the Commissioner is authorized to debit any necessary fee to said deposit account.

05/12/1999 AIBRAHIM 00000027 192570 08945249

01 FC:116 380.00 CH

Respectfully submitted,



Dara L. Dinner
Attorney for Applicants
Registration No. 33,680

SMITHKLINE BEECHAM CORPORATION
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5017
Facsimile (610) 270-5090

RECEIVED

MAY 12 1999

MATRIX CUSTOMER
SERVICE CENTER



P31158

CERTIFICATE OF MAILING
I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE
UNITED STATES POSTAL SERVICE AS FIRST-CLASS MAIL IN AN ENVELOPE
ADDRESSED TO: ASSISTANT COMMISSIONER OF PATENTS, WASHINGTON, D.C.

20231 ON 7 May 1999

AGENT ATTORNEY FOR APPLICANT

DATE

#121
CH/CC
5-14-99

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Vere Hodge et al. 7 May 1999
Serial No.: 08/945,249 Group Art Unit No.: 1614
Filed: 2 February 1998 Examiner: R. Travers
For: Use of (R)-Penciclovir Triphosphate For the Manufacture of A Medicament
For the Treatment of Viral Diseases

Assistant Commissioner of Patents
Washington, D.C. 20231

RESPONSE

Sir:

In response to the Examiner's Action mailed 5 January 1999, having a shortened statutory period of three(3) months, please enter the following Remarks and Amendments into the record. Also enclosed herewith is a petition for a two (2) month extension of the shortened statutory period set by the Examiner and authorization to charge the required fee to the indicated deposit account.

In the Claims:

Please cancel Claim 15.

Please amend the following claims:

Claim 4 (2x amended). The method according to Claim 1 wherein the (R)-PCV-TP is in the form of a bioprecursor which is a [derivative of (R)-PCV-MP] PL-ASOR derivative, phospholipid derivative, (R)-MP Bis(POM) derivative, (R)-MP diphenyl ester derivative, or dimyristoylglycerol diphosphate derivative of (R)-PCV-MP which liberates intracellularly (R)-PCV-MP which is in turn converted to (R)-PCV-TP.

Claim 16 (amended). The method according to Claim [15] 4 wherein the [bioprecursor] PL-ASOR derivative is a PL-ASOR derivative.

MAY 12 1999

MATHIAS
SERVICES